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ABSTRACT  
The purpose of this research was to develop fast dissolving oral film of Escitalopram oxalate. Fast dissolving oral film offers a solution for 
paediatrics, geriatrics; psychiatric or mentally ill people and those have difficulty in swallowing tablets/capsules resulting in improved patient 
compliance. Selective serotonin reuptake inhibitors (SSRIs), which are broad spectrum antidepressants that are effective for major depressive 
disorder and several anxiety disorders. Escitalopram Oxalate is highly selective, more effective and better than other SSRIs.  The prepared 
formulations were evaluated for Thickness, Weight uniformity, Folding Endurance, Percentage of Moisture Content, Drug Content Analysis, 
Disintegrating time and In vitro dissolution study. Stability studies were carried out with optimized formulation F5 which was stored for a 
period of one, two and three months at 40±2oC temperature and 75±5% relative humidity for a period 3 months.  Thus it can be concluded that 
Escitalopram oxalate fast dissolving films could be commercially exploited for the treatment of panic disorder using Escitalopram oxalate with 
merits of faster onset of action, avoidance of extensive first pass metabolism, low dosage regimen, enhanced bioavailability and improved 
patient compliance. 
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INTRODUCTION 
Escitalopram oxalate is a newer antidepressant used for the 
treatment of panic disorder. Escitalopram oxalate is S(+) 
enantiomer of the racemic bicyclic phthalene derivative of 
citalopram, which is chemically S(+)-1-
[3(dimethylamino)propyl]-1-p-flurophenyl-5-phthalene 
carbonitrile1-2. 
Escitalopram oxalate acts by increasing intrasynaptic levels 
of the neurotransmitter serotonin by blocking the reuptake 
of the neurotransmitter into the neuron. Its half-life is about 
27-32 hours. It is metabolized in the liver, especially by the 
CYP3A4 and CYP2C19 after oral administration. Its 
bioavailability is 80% and protein binding is approximately 
56%. It is poorly soluble in water so its absorption is less. It 
is acidic and its pKa value is 4.19 which is satisfactory for 
selection of drug. The Log Partition coefficient value is 3.45. 
The tmax value of Escitalopram oxalate is 4hr after multiple 
dosing. The dose of 5-20mg once a day and is used for 
treatment of depression3. 
This is seen to afflict nearly 45% of the general population. 
Particularly, the difficulty is experienced by pediatric and 
geriatric patients3. To overcome these problems, 
orodispersible film have been developed, which has good 
dose uniformity, easy administration and serves as the first 
choice of dosage form for pediatrics, geriatrics and travelling 
patients.  Fast-dissolving oral films (FDFs) showed a great 
potential over other dosage forms for the delivery of drugs 
since they provide distinct advantages including rapid 
disintegration and dissolution in the oral cavity thus increase 
bioavailability with faster onset of action and avoidance of 
first-pass effect 4. Due to high permeability of oral mucosa, it 
allows direct access of drug to the systemic circulation and 
avoids the first pass metabolism5. FDFs represent an 
advantageous dosage form, especially for geriatric and 
pediatric patients6-7.  
MATERIALS AND METHODS  
Materials 
Escitalopram oxalate was obtained as a gift sample from 
Pharmaceutical Company. HPMC was procured from 
Qualikems fine chem Pvt Ltd Vadodhara. PEG400, sodium 
starch glycolate, croscarmellose sodium was obtained from 
S.D fine chemicals limited, Mumbai. Citric acid, ethanol was 
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obtained from Loba Chemical Pvt Ltd (Mumbai, India). 
Hydrochloric acid, KH2 PO4, NaoH was obtained from S. D. 
Fine Chem. Ltd., Mumbai. All other chemical were purchased 
from Hi Media, Mumbai. Double distilled water was prepared 
freshly and used whenever required. All the chemicals used 
in this work were of analytical grade. 
Standardization of Escitalopram oxalate by UV-Visible 
spectrophotometry 
Determination of λ max of Escitalopram oxalate 
The λmax of Escitalopram oxalate was determined by running 
the spectrum of drug solution in double beam ultraviolet 
spectrophotometer (Labindia 3000+). Accurately weighed 10 
mg of drug was dissolved in 10 ml of Phosphate buffer pH 6.8 
solutions in 10 ml of volumetric flask. The resulted solution 
(1000µg/ml) was used to prepare the concentration 
10μg/ml. The spectrum of this solution was recorded in 200-
400 nm range using U.V. spectrophotometer (Labindia-
3000+) 8. After the complete scan λmax of Escitalopram 
oxalate was found 232 nm. 
Preparation of calibration curve: 
From stock solutions of Escitalopram oxalate 1 ml was taken 
and diluted up to 10 ml. from this solution 0.5, 1.0, 1.5, 2.0 
and 2.5 ml solutions were transferred to 10ml volumetric 
flasks and make up the volume up to 10 ml with Phosphate 
buffer pH 6.8, gives standard drug solution of 5, 10, 15, 20, 
25μg/ ml concentration. 
Formulation development of oral film of Escitalopram 
oxalate 
Solvent casting technique 
Drug (Escitalopram oxalate) containing fast dissolving films 
were fabricated by the solvent casting method. The 
optimized amount of HPMC was dissolved in 5ml of water 
and stirrer continuously for 1 hour, optimized amount of 
plasticizer and drug were dissolved in 95% ethanol and then 
added to the polymeric solution, Polymeric solution was 
stirred for 30 min using magnetic stirrer and was kept in 
undisturbed condition till the entrapped air bubbles were 
removed. The aqueous solution was casted in a glass moulds 
having 2.5 x 2.5 cm * 10 films area and was dried at 
controlled room temperature (25°-30°C, 45 %RH) as well as 
at increased temperature (microwave oven). The film took 
approximately 48 hr to dry at controlled room temperature. 
The dried film was carefully removed from the glass plates 
and was cut into size required for testing. The films were 
stored in air tight plastic bags till further use. Formulations 
were prepared using HPMC K15, PEG-400, SSG and CCS at 
different drug: polymer ratios. The compositions of the 
formulations were shown in table 1. 
 
 
Table 1: Formulation of Escitalopram oxalate oral fast dissolving films 
Name of ingredients (mg) 
(mg for 12 strips) 
F1 F2 F3 F4 F5 F6 
Escitaloprám oxalate  120 120 120 120 120 120 
HPMC 300 600 900 300 600 900 
PEG-400 150 150 150 150 150 150 
SSG 200 300 400 - - - 
CCS - - - 200 300 400 
Mannitol 100 100 100 100 100 100 
Citric acid 100 100 100 100 100 100 
DM water  qs to (ml) 30 30 30 30 30 30 
  
 
Dose calculations 
 Width of the plate = 5cm 
 Length of the plate = 12cm 
 No. of 2.5 x 2.5 cm2 films present whole plate = 12 
 Each film contains 10 mg of drug. 
 12 no. of films contains mg of drug? = 10×12 = 120mg 
 The amount of Escitalopram oxalate added in each 
plate was approximately equal to 10mg. 
Evaluation 
The formulations were evaluated by the following tests 9-12. 
 
Thickness 
Randomly 10 films were selected and thickness was 
measured using vernier calliper at three different places. 
Weight variation  
For each formulation, three randomly selected patches were 
used. For weight variation test, 10 films from each batch 
were weighed individually by digital electronic balance and 
the average weight was calculated. 
Folding endurance 
This was determined by repeatedly folding one film at the 
same place until it broke. The number of times the film could 
be folded at the same place without breaking cracking gave 
the value of folding endurance.  
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Percentage of moisture content 
The films were weighed individually and kept in desiccators 
containing activated silica at room temperature for 24 hrs. 
Individual films were weighed repeatedly until they showed 
a constant weight. The percentage of moisture content was 
calculated as the difference between initial and final weight 
with respect to final weight.  
Drug content analysis 
The patches (n = 3) of specified area were taken into a 10 ml 
volumetric flask and dissolved in methanol and volume was 
made up with 10 ml methanol. Subsequent dilutions were 
made and analyzed by UV spectrophotometer at 232nm.  
Disintegrating time 
The most important criteria of present work are to that 
dosage form should be dissolved within few seconds. The 
incorporation of super disintegrating agent to minimizes the 
disintegrating time. Three super disintegrating agent were 
selected for this work. The film of (2.5*2.5 cm) size (unit 
dose) was placed on a petridish containing 10 ml of distilled 
water. The time required for the film to break was noted as 
cursive in vitro disintegration time. 
In vitro dissolution study  
The in vitro dissolution test was performed using the USP 
dissolution apparatus II (Paddle with sinker). The 
dissolution studies were carried out at 37±0.5°C; with 
stirring speed of 50 rpm in 900 ml phosphate buffer (pH 6.8). 
Film size required for dose delivery (2.5×2.5 cm2) was used. 
Five ml aliquot of dissolution media was collected at time 
intervals of 1, 2 and 5 minutes and replaced with equal 
volumes of phosphate buffer (pH 6.8). The collected samples 
were filtered through 0.45 μm membrane filter and the 
concentration of the dissolved Escitalopram oxalate was 
determined using UV-Visible spectrophotometer at 232nm. 
The results were presented as an average of three such 
concentrations. 
Stability studies 
Stability studies were carried out with optimized 
formulation which was stored for a period of one, two and 
three months at 40±2oC temperature and 75±5% relative 
humidity for a period 3 months. The % Assay of formulation 
was determined by U.V. spectrophotometer using calibration 
curve method.  
RESULTS AND DISCUSSION 
To check solubility of drug in other solvent like water, 
ethanol, methanol, 0.1 N HCl, 0.1 N NaOH, Chloroform and 
6.8 pH Phosphate buffer.  Melting point was determined by 
Melting point apparatus (Chemiline CL-725) and found to 
150-151°C. The λmax found for Escitalopram oxalate is 232.0 
nm. Various methods are available for casting of oral films. 
This is fast disintegrating oral film hence on the laboratory 
scale solvent casting technique was adopted for formulation 
of films. In the present work, fast dissolving oral films of 
Escitalopram oxalate were prepared by solvent casting 
method with a view to enhance patient compliance, for the 
treatment of depression. Fast dissolving oral films were 
disintegrated in the mouth and were dissolved within a 
matter of few seconds without need of water. Fast dissolving 
oral films were prepared using different concentration of 
superdisintegrants and evaluated. Different formulations 
(F1-F6) were prepared using varying amount of SSG and CCS. 
The prepared formulations were evaluated for Thickness, 
Weight uniformity, Folding Endurance, Percentage of 
Moisture Content, Drug Content Analysis, Disintegrating time 
and In vitro dissolution study. Stability studies were carried 
out with optimized formulation F5 which was stored for a 
period of one, two and three months at 40±2oC temperature 
and 75±5% relative humidity for a period 3 months. The % 
Assay of formulation was determined by U.V. 
spectrophotometer using calibration curve method. The % 
assay of film was found to slightly decrease at higher 
temperature.  
 
 
Figure 1: U.V. Spectra of Pure Drug (Escitalopram 
oxalate) 
 
G) Calibration curve of Escitalopram oxalate at λ max 
232nm 
Observation table: 
Table 2: Calibration curve of Escitalopram oxalate in 
Phosphate buffer pH 6.8 
S. No. Conc. (µg/ml)  Absorbance 
1. 2 0.207 
2. 4 0.378 
3. 6 0.534 
4. 8 0.685 
5. 10 0.871 
 
 
Figure 2: Calibration Curve of Escitalopram oxalate in 
Phosphate buffer pH 6.8 at 232nm
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Table 3: Result of general appearance, thickness, weight variation and % assay 
Formulation code General 
Appearance 
Thickness* 
 (µm) 
Weight* 
 (mg) 
(%) Assay*  
F1 Translucent 0.09±0.01 85 96.65±0.12 
F2 Translucent 0.10±0.02 122 97.56±0.21 
F3 Translucent 0.12±0.02 153 96.45±0.14 
F4 Translucent 0.08±0.01 86 97.45±0.32 
F5 Translucent 0.12±0.02 125 99.85±0.14 
F6 Translucent 0.13±0.02 155 98.85±0.25 
*Average of three determination (n=3) 
 
Table 4: Result of folding endurance, disintegrating time, tensile strength &% of moisture content 
Formulation 
code 
Folding 
endurance*  
Disintegration 
time (Sec.)* 
Tensile strength  
(kg/cm2)* 
Moisture Content 
(%)* 
F1 More than 100 88±4 0.658±0.008 2.23±0.12 
F2 More than 100 80±5 0.698±0.006 2.10±0.14 
F3 More than 100 73±3 0.712±0.007 1.85±013 
F4 More than 100 66±5 0.612±0.006 1.65±14 
F5 More than 100 50±4 0.756±0.005 1.21±12 
F6 More than 100 60±5 0.763±0.004 1.92±11 
*Average of three determination (n=3) 
 
Table 5: Results of In-Vitro release study of optimized formulation F3 
S. No. Time (Min.) Cumulative % Drug release 
1. 1 33.45±0.45 
2. 2 67.85±0.65 
3. 5 96.65±0.32 
 
Table 6: Characterization of stability study of optimized film (F3) 
Characteristic 
Time (Month) 
Initial 1 Month 2 Month 3 Month 
% Assay*  99.12±0.45 98.45±0.32 98.12±0.45 98.05±0.65 
*Average of three determination (n=3) 
 
CONCLUSION 
Fast dissolving oral films were prepared using different 
concentration of superdisintegrants and evaluated. Different 
formulations (F1-F6) were prepared using varying amount 
of SSG and CCS. The prepared formulations were evaluated 
for thickness, weight uniformity, folding endurance, 
percentage of moisture content, drug content analysis, 
disintegrating time and In vitro dissolution study. Stability 
studies were carried out with optimized formulation F5 
which was stored for a period of one, two and three months 
at 40±2oC temperature and 75±5% relative humidity for a 
period 3 months. The % Assay of formulation was 
determined by U.V. spectrophotometer using calibration 
curve method. The % assay of film was found to slightly 
decrease at higher temperature.  Results of evaluation 
parameters of optimized and validated Escitalopram oxalate 
oral fast dissolving films revealed good mechanical strength, 
uniformity of content, optimum surface pH, faster 
disintegration time, almost complete drug dissolution or 
release and good stability up to three months. Thus it can be 
concluded that Escitalopram oxalate fast dissolving films 
could be commercially exploited for the treatment of panic 
disorder using Escitalopram oxalate with merits of faster 
onset of action, avoidance of extensive first pass metabolism, 
low dosage regimen, enhanced bioavailability and improved 
patient compliance. 
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